Teladoc Health TDOC Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$63.84M-154% | -$25.14M+49.2% | -$49.51M-51.6% | -$32.66M+64.9% | -$93.01M-92.1% | ||
| $14.61M-8.2% | $15.91M-6.4% | $17M-23.9% | $22.34M-11.2% | $25.16M-8.4% | ||
| -$1.06M+89.4% | -$9.96M— | $0+100% | -$7.21M+73.2% | -$26.87M-1,430% | ||
| $0— | $0-100% | $12.63M— | $0-100% | $59.14M— | ||
| -$79K-116% | $482K+156% | -$858K-370% | $318K+439% | $59K-96.3% | ||
| $21M+220% | -$17.46M-8.1% | -$16.16M-139% | -$6.77M-144% | $15.27M+277% | ||
| -$6.32M-339% | -$1.44M-176% | $1.9M— | —— | -$1.52M-207% | ||
| -$2.11M— | —— | —— | $1.92M-88.9% | $17.36M+484% | ||
| -$31.53M-274% | $18.09M— | —— | —— | -$21.46M— | ||
| $29.45M+467% | -$8.01M— | —— | —— | $23.79M+1,117% | ||
| -$82K+97.7% | -$3.61M— | $0+100% | -$114K+97.0% | -$3.8M— | ||
| -$1.33M+57.5% | -$3.13M-156% | -$1.22M-313% | -$296K+83.1% | -$1.75M+61.8% | ||
| $5.06M+151% | -$9.99M-170% | -$3.69M-581% | -$542K+90.2% | -$5.54M+28.9% | ||
| $89.83M-2.4% | $92.04M+7.3% | $85.76M-3.3% | $88.66M+5.2% | $84.3M-2.6% | ||
| $1.9M-56.7% | $4.38M+15.9% | $3.78M+101% | $1.89M-18.2% | $2.31M+7.2% | ||
| -$2.3M+32.0% | -$3.38M+33.5% | -$5.08M-89.0% | -$2.69M-8.3% | -$2.48M+11.5% | ||
| $9.52M-89.2% | $87.74M-11.6% | $99.26M+8.6% | $91.43M+474% | $15.92M-81.5% | ||
| $1.66M-36.6% | $2.62M+14.9% | $2.28M+79.8% | $1.27M-53.5% | $2.73M-55.5% | ||
| $0— | $0-100% | $16.6M+2,292% | $694K-98.9% | $64.61M— | ||
| $700K— | —— | $800K— | —— | $27.08M— | ||
| -$36.52M-6.4% | -$34.32M+29.6% | -$48.72M+18.4% | -$59.7M+51.6% | -$123.27M-316% | ||
| $0-100% | $4K— | $0-100% | $1K-98.8% | $80K-90.6% | ||
| -$2.85M— | $0— | $0— | $0— | $0— | ||
| -$2.45M— | $0+100% | -$3.59M+99.3% | -$549.93M-71,613% | $769K-62.6% | ||
| -$891K-389% | $308K— | $0-100% | $4.49M+183% | $1.59M+141% | ||
| -$29.46M— | —— | —— | -$518.2M-386% | -$106.58M-283% | ||
| -$42K-101% | $2.98M+2,765% | $104K-98.0% | $5.33M+1,526% | $328K-80.8% | ||
| $89.83M-2.4% | $92.04M+7.3% | $85.76M-3.3% | $88.66M+5.2% | $84.3M-2.6% | ||
| $2.46M-12.1% | $2.8M+7.2% | $2.61M-39.8% | $4.34M+21.7% | $3.56M+19.6% | ||
| $39.11M+289% | -$20.74M— | —— | -$17.72M-241% | $12.57M-22.4% | ||
| -$31.53M-274% | $18.09M— | —— | —— | -$21.46M— | ||
| -$2.3M+32.0% | -$3.38M+33.5% | -$5.08M-89.0% | -$2.69M-8.3% | -$2.48M+11.5% | ||
| -$82K+97.7% | -$3.61M— | $0+100% | -$114K+97.0% | -$3.8M— | ||
| -$336K+79.1% | -$1.61M— | —— | -$7.2M-1,649% | -$412K-115% | ||
| $29.45M+467% | -$8.01M— | —— | —— | $23.79M+1,117% | ||
| $1.9M-56.7% | $4.38M+15.9% | $3.78M+101% | $1.89M-18.2% | $2.31M+7.2% | ||
| -$1.33M+57.5% | -$3.13M-156% | -$1.22M-313% | -$296K+83.1% | -$1.75M+61.8% | ||
| -$79K-116% | $482K+156% | -$858K-370% | $318K+439% | $59K-96.3% | ||
| $34.16M+7.8% | $31.7M+9.2% | $29.04M+0.3% | $28.97M+0.4% | $28.86M+22.7% | ||
| -$2.85M— | $0— | $0— | $0— | $0— | ||
| $399K— | —— | —— | —— | $689K-42.0% | ||
| $5.06M+151% | -$9.99M-170% | -$3.69M-581% | -$542K+90.2% | -$5.54M+28.9% | ||
| -$2.3M+32.0% | -$3.38M+33.5% | -$5.08M-89.0% | -$2.69M-8.3% | -$2.48M+11.5% | ||
| $4.82M-66.9% | $14.57M+623% | $2.02M+42.9% | $1.41M-67.0% | $4.27M+562% | ||
| -$42K-101% | $2.98M+2,765% | $104K-98.0% | $5.33M+1,526% | $328K-80.8% | ||
| $7.86M-90.8% | $85.12M-12.2% | $96.98M+7.6% | $90.16M+583% | $13.19M-83.5% | ||
| $7.86M-90.8% | $85.12M-12.2% | $96.98M+7.6% | $90.16M+583% | $13.19M-83.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Teladoc Health generate?
- Teladoc Health (TDOC) generated $288.0M in operating cash flow over the trailing twelve months.
- What is Teladoc Health's free cash flow?
- After $7.8M of capital expenditures, Teladoc Health's free cash flow was $280.1M over the trailing twelve months, down 2.8% year over year.
- Where does Teladoc Health's cash flow data come from?
- Every line is extracted from Teladoc Health's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
